Total synthesis of plagiochins C and D, macrocyclic bis(bibenzyl) constituents of plagiochila acantophylla
摘要:
Plagiochins C (3) and D (4) were synthesized by convergent schemes. Rings C and B were joined by Ullman ether synthesis, the aryl-aryl bond between rings A and D was formed by Pd(0)-catalysed coupling of an arylboronic acid (ring D) and a bromobenzoic ester (ring A). Ring C and D were linked by the Wittig reaction, while final ring closure was effected by tetraphenylethene assisted Wurtz reaction.
Total synthesis of plagiochins C and D, macrocyclic bis(bibenzyl) constituents of plagiochila acantophylla
摘要:
Plagiochins C (3) and D (4) were synthesized by convergent schemes. Rings C and B were joined by Ullman ether synthesis, the aryl-aryl bond between rings A and D was formed by Pd(0)-catalysed coupling of an arylboronic acid (ring D) and a bromobenzoic ester (ring A). Ring C and D were linked by the Wittig reaction, while final ring closure was effected by tetraphenylethene assisted Wurtz reaction.
The hydroboration/Pd-catalyzed migrative Suzuki–Miyaura cross-coupling of 1,3-dienes with electron-deficient arylhalides has been developed, which enables the synthesis of branched allylarenes directly from primary homoallylic alkyl boranes. A ligand-tuned linear- or branch-selective coupling for these arylhalides has also been achieved.
PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE
申请人:Genentech, Inc.
公开号:US20170095570A1
公开(公告)日:2017-04-06
The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
Pyrrolobenzodiazepine antibody drug conjugates and methods of use
申请人:Genentech, Inc.
公开号:US10058613B2
公开(公告)日:2018-08-28
The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.